欧盟抗菌剂开发的可转让独家代金券和激励措施。

IF 1.6 4区哲学 Q2 ETHICS Journal of Law Medicine & Ethics Pub Date : 2023-01-01 DOI:10.1017/jme.2023.58

Victor L Van de Wiele, Adam Raymakers, Aaron S Kesselheim, Benjamin N Rome

{"title":"欧盟抗菌剂开发的可转让独家代金券和激励措施。","authors":"Victor L Van de Wiele, Adam Raymakers, Aaron S Kesselheim, Benjamin N Rome","doi":"10.1017/jme.2023.58","DOIUrl":null,"url":null,"abstract":"The European Commission's proposal to address antimicrobial resistance using transferable exclusivity vouchers (TEVs) is fundamentally flawed. European policymakers and regulators should consider alternatives, such as better funding for basic and clinical research, use of advance market commitments funded by a pay-or-play tax, or enacting an EU Fund for Antibiotic Development.","PeriodicalId":50165,"journal":{"name":"Journal of Law Medicine & Ethics","volume":null,"pages":null},"PeriodicalIF":1.6000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Transferable Exclusivity Vouchers and Incentives for Antimicrobial Development in the European Union.\",\"authors\":\"Victor L Van de Wiele, Adam Raymakers, Aaron S Kesselheim, Benjamin N Rome\",\"doi\":\"10.1017/jme.2023.58\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The European Commission's proposal to address antimicrobial resistance using transferable exclusivity vouchers (TEVs) is fundamentally flawed. European policymakers and regulators should consider alternatives, such as better funding for basic and clinical research, use of advance market commitments funded by a pay-or-play tax, or enacting an EU Fund for Antibiotic Development.\",\"PeriodicalId\":50165,\"journal\":{\"name\":\"Journal of Law Medicine & Ethics\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.6000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Law Medicine & Ethics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1017/jme.2023.58\",\"RegionNum\":4,\"RegionCategory\":\"哲学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ETHICS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Law Medicine & Ethics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1017/jme.2023.58","RegionNum":4,"RegionCategory":"哲学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ETHICS","Score":null,"Total":0}

引用次数: 0

摘要

欧盟委员会提出的使用可转让排他性凭证(tev)解决抗菌素耐药性问题的建议存在根本性缺陷。欧洲的政策制定者和监管机构应该考虑其他替代方案，比如为基础和临床研究提供更好的资金，使用由“即付即用”税资助的预先市场承诺，或者制定欧盟抗生素开发基金。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Transferable Exclusivity Vouchers and Incentives for Antimicrobial Development in the European Union.

The European Commission's proposal to address antimicrobial resistance using transferable exclusivity vouchers (TEVs) is fundamentally flawed. European policymakers and regulators should consider alternatives, such as better funding for basic and clinical research, use of advance market commitments funded by a pay-or-play tax, or enacting an EU Fund for Antibiotic Development.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of Law Medicine & Ethics 医学-医学：法

CiteScore

2.90

自引率

4.80%

发文量

审稿时长

6-12 weeks

期刊介绍： Material published in The Journal of Law, Medicine & Ethics (JLME) contributes to the educational mission of The American Society of Law, Medicine & Ethics, covering public health, health disparities, patient safety and quality of care, and biomedical science and research. It provides articles on such timely topics as health care quality and access, managed care, pain relief, genetics, child/maternal health, reproductive health, informed consent, assisted dying, ethics committees, HIV/AIDS, and public health. Symposium issues review significant policy developments, health law court decisions, and books.